Bristol-Myers Squibb: Melanoma trials

The registry lists 106 Melanoma studies with Bristol-Myers Squibb as lead sponsor. 3 are open to participants now and 42 have results posted.

Phase 1 23Phase 2 30Phase 3 23Phase 4 1No phase 35(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideCompletedNCT00135408Phase 2
• Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney CancerCompletedNCT00095108Phase 1
• Trial of ABI-007 in Previously Treated Patients With Metastatic MelanomaCompletedNCT00093119Phase 2
• Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.CompletedNCT00057616Phase 3
• Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant MelanomaCompletedNCT00055562Phase 2/3
• Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic MelanomaCompletedNCT00050102Phase 2